Danish drugmaker reaches settlement with US authorities

COPENHAGEN, Denmark (AP) — Danish drug maker Novo Nordisk says it has reached a $46.5 million settlement with U.S. authorities over allegations that it hadn't properly communicated safety information when marketing a medicine to treat type 2 diabetes.

Novo Nordisk says it also will pay $12.15 million to resolve a complaint filed by the government on behalf of the U.S. Food and Drug Administration in federal court.

Douglas Langa, head of Novo Nordisk's North America operations, said late Tuesday that the Copenhagen-based company denies "any wrongdoing" but was pleased with the case's resolution.